We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
76
CALL
Cabaletta Bio
CABA
$437M
$1.6M 0.24%
+423,000
New +$4.51M
LQDA icon
77
Liquidia Corp
LQDA
$7.48B
$1.58M 0.24%
325,445
-559,448
-63% -$2.23M
IFRX icon
78
InflaRx
IFRX
$250M
$1.58M 0.23%
331,048
-300,000
-48% -$1.21M
NTBL
79
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.56M 0.23%
22,595
– –
RNTX
80
Rein Therapeutics
RNTX
$63.1M
$1.56M 0.23%
138,179
– –
ELDN icon
81
Eledon Pharmaceuticals
ELDN
$261M
$1.52M 0.23%
344,578
– –
OKUR
82
OnKure Therapeutics
OKUR
$154M
$1.5M 0.22%
17,500
– –
PHAT icon
83
Phathom Pharmaceuticals
PHAT
$708M
$1.47M 0.22%
74,560
-25,000
-25% -$588K
CNTB
84
Connect Biopharma Holdings
CNTB
$127M
$1.35M 0.2%
+262,237
New +$2.91M
MXCT icon
85
MaxCyte
MXCT
$112M
$1.32M 0.2%
130,000
-20,000
-13% -$215K
VSTM icon
86
Verastem
VSTM
$510M
$1.31M 0.19%
53,114
-49,167
-48% -$1.55M
TAOX
87
Tao Synergies Inc
TAOX
$24.6M
$1.24M 0.18%
5,825
-4,000
-41% -$1M
IRON icon
88
Disc Medicine
IRON
$2.94B
$1.23M 0.18%
14,035
– –
AVTX icon
89
Avalo Therapeutics
AVTX
$965M
$1.22M 0.18%
250
– –
GRI
90
GRI Bio
GRI
$2.44M
– –
0
– –
SYBX
91
DELISTED
Synlogic
SYBX
$1.17M 0.17%
32,255
-20,333
-39% -$790K
PLRX icon
92
Pliant Therapeutics
PLRX
$64.4M
$1.17M 0.17%
86,712
– –
RIGL icon
93
Rigel Pharmaceuticals
RIGL
$681M
$1.16M 0.17%
+43,936
New +$1.33M
CRVS icon
94
Corvus Pharmaceuticals
CRVS
$1.12B
$1.16M 0.17%
482,610
-274,935
-36% -$1.07M
BCLI
95
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.16M 0.17%
19,303
– –
QSI icon
96
Quantum-Si Incorporated
QSI
$155M
$1.14M 0.17%
144,406
– –
ASND icon
97
Ascendis Pharma A/S
ASND
$16B
$1.13M 0.17%
+8,400
New +$1.25M
DBVT
98
DBV Technologies
DBVT
$799M
$1.08M 0.16%
31,011
– –
ANEB
99
DELISTED
Anebulo Pharmaceuticals
ANEB
$1.07M 0.16%
172,309
– –
AVIR icon
100
CALL
Atea Pharmaceuticals
AVIR
$376M
$1.04M 0.16%
116,600
– –
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.